تحميل...
P469 The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
BACKGROUND: SB5, a biosimilar to reference adalimumab, received EU marketing authorisation in August 2017, based on pre-clinical and clinical Phase I and III studies that demonstrated bioequivalence, similar efficacy, and comparable safety and immunogenicity to the reference. The ongoing real-world...
محفوظ في:
| الحاوية / القاعدة: | J Crohns Colitis |
|---|---|
| المؤلفون الرئيسيون: | , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Oxford University Press
2021
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8194725/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjab076.592 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|